Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This research is designed to obtain efficacy and safety information for 123-I IMPY as an
imaging biomarker for Alzheimer's disease (AD). The distribution of this agent will be
measured by obtaining single photon emission computed tomography (SPECT) images of the brain
serially over time to determine the relative localization of the radiopharmaceutical in
regions of the cortex relative to background regions and develop an optimal technique of
radiotracer administration (bolus or bolus with constant infusion). The researchers will then
evaluate the utility of 123-I IMPY and SPECT in AD patients as an early diagnostic tool and
subsequently serial evaluations of AD patients will be performed to determine if this
technique may be useful as a tool for evaluation of progressive brain β-amyloid deposition in
AD.